台湾生物技术公司SynbioTech(SynbioTech)在2025年达芬奇博览会上因其先进的抗生素赢得了五枚金牌,已证明对老年人和透析病人有效。 SynbioTech, a Taiwan biotech firm, won five gold medals at the 2025 Da Vinci Expo for its advanced probiotics, proven effective for seniors and dialysis patients.

台湾生物技术公司SynbioTech(SynbioTech)在2025年达芬奇国际发明博览会上赢得了五枚金牌,以表彰其先生创新,包括ABKEFIR、LDL557后生和SynForU-ReMain。 SynbioTech, a Taiwan-based biotech company, won five gold medals at the 2025 Da Vinci International Invention Expo for its probiotic innovations, including ABKEFIR, LDL557 Postbiotic, and SynForU-ReMain. 这些产品使用专有的共生发酵和SYNTEK技术,将抗生素能提高50%以上,临床试验显示,对老年人和透析病人的肠胃健康、免疫功能、联合炎症和肾脏支持都有好处。 The products use proprietary symbiotic fermentation and SYNTEK technology to boost probiotic potency by over 50%, with clinical trials showing benefits for gut health, immune function, joint inflammation, and kidney support in seniors and dialysis patients. 该公司成立于2000年,拥有60个专利,拥有一个大型乳酸细菌菌株库,供应台湾一半以上的卫生食品品牌。 The company, founded in 2000, holds 60 patents, maintains a large lactic acid bacteria strain bank, and supplies over half of Taiwan’s health food brands. 它在全球开展业务,并计划向东南亚、澳大利亚和南亚扩展,重点是人口老龄化人口。 It operates globally and plans to expand into Southeast Asia, Australia, and South Asia, focusing on aging populations.